RDNT vs SIEGY: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: SIEGY is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. RDNT and SIEGY share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined RDNT and SIEGY exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

RadNet operates a network of several hundred outpatient imaging centers, mostly clustered in dense markets such as California, the Northeast, Maryland and Florida, and many of them are run in joint venture with local hospitals and health systems. The centers perform MRI, CT, PET, mammography, ultrasound and X-ray, and revenue comes primarily from commercial insurers, Medicare and Medicaid, plus a growing slice of self-pay screening. A second reporting segment, Digital Health, houses DeepHealth, the company's radiology AI and software business, which sells clinical AI tools, imaging workflow software and an enhanced breast cancer detection add-on that patients often pay for directly. The 2026 acquisition of Gleamer widened that segment's product range and installed base internationally.

Full RDNT guide

Siemens AG is one of Europe's largest industrial technology companies, headquartered in Munich. It runs four main businesses: Digital Industries (factory automation hardware such as PLCs and drives, plus industrial software including Xcelerator, Teamcenter, NX and the recently acquired Altair and Dotmatics), Smart Infrastructure (electrical products, grid technology and building systems, a big beneficiary of data center and electrification spending), Mobility (rail vehicles, signaling and rail software), and a roughly 67% stake in Siemens Healthineers, the medical imaging and diagnostics company that Siemens plans to separate. Fiscal years end on September 30, and US investors typically hold the company through the SIEGY sponsored ADR, which trades over the counter in dollars rather than on a US exchange. The company employs roughly 300,000 people, sells in close to 190 countries and generates a large share of revenue outside Germany, with the US and China among its biggest markets.

Full SIEGY guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• RDNT drivers: The site-of-care shift out of hospitals; Digital Health and the DeepHealth stack.
• SIEGY drivers: Electrification and data center demand at Smart Infrastructure; Industrial software and the Altair and Dotmatics deals.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Reimbursement is set largely by Medicare and by commercial contracts, so a rate cut or an unfavorable contract renewal flows almost straight to operating income. For SIEGY, siemens is cyclical at the margin: an industrial slowdown, weaker China demand or a pause in data center spending would hit orders and the premium multiple at the same time.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick RDNT if you believe its drivers more; SIEGY if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the RDNT and SIEGY guides.

RDNT. At roughly $5.5B of market value on roughly $2.27B of trailing revenue, RDNT trades near 2.4 times sales and about 26 times EV/EBITDA for a business whose GAAP bottom line is around breakeven, so the multiple is being carried by adjusted EBITDA, free cash flow growth and the Digital Health segment rather than by earnings. The second quarter beat on both revenue growth (~25%) and EPS, yet the shares are down about 1.6% in 2026 and about 9.7% over a year, sitting between a 52-week low of ~$50.82 and high of ~$85.84. Consensus looks for 2026 revenue of ~$2.51B and EPS of ~$0.51, and the November 5 report is the next check.

SIEGY. At a Frankfurt share price around €240, Siemens trades at roughly 21 times the midpoint of its raised fiscal 2026 EPS guidance, a premium to its own history and to many diversified industrials but below pure-play electrification and automation names such as Schneider Electric. The SIEGY ADR represents one-half of an ordinary share, so its dollar price is roughly half the euro share price converted at the current exchange rate. Full fiscal 2026 results are due in mid-November 2026. The quarterly cadence matters for ADR holders: results arrive in November, February, May and August, and the ADR typically reacts in the US session following the morning German release.

Headline figures (approximate, October 2026): RDNT shows market cap ~$5.5B at $69.85 (October 16, 2026), revenue (ttm) ~$2.27B, against ~$2.04B for fiscal 2025, q2 2026 revenue ~$622.7M, up ~25% year over year, after ~$575.6M in Q1, q2 2026 eps vs estimate ~$0.29 against a ~$0.20 consensus; Q1 was ~-$0.28 against ~-$0.19; SIEGY shows revenue (ttm) ~€81 billion, fiscal q3 2026 orders ~€27.9 billion (book-to-bill ~1.34), order backlog ~€132 billion, fy2026 eps pre-ppa guidance ~€11.20 to €11.50.

RDNT and SIEGY are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined RDNT and SIEGY exposure against your real portfolio. It is not an investment adviser.